Stealth BioTherapeutics Corp (NASDAQ:MITO) Receives $24.83 Average Price Target from Analysts

Shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) have received a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $26.60.

A number of research analysts have weighed in on MITO shares. HC Wainwright set a $5.00 target price on Eyepoint Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 12th. Zacks Investment Research lowered Tupperware Brands from a “hold” rating to a “sell” rating in a report on Thursday.

Stealth BioTherapeutics stock traded up $0.24 during midday trading on Friday, reaching $11.24. The stock had a trading volume of 2,694 shares, compared to its average volume of 5,247. The firm has a market cap of $307.34 million and a price-to-earnings ratio of -7.97. Stealth BioTherapeutics has a 12 month low of $11.00 and a 12 month high of $20.99. The business has a 50-day moving average of $12.42.

Stealth BioTherapeutics (NASDAQ:MITO) last posted its earnings results on Wednesday, May 15th. The company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.14. As a group, equities analysts forecast that Stealth BioTherapeutics will post -0.18 EPS for the current year.

A hedge fund recently bought a new stake in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC bought a new stake in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned approximately 0.18% of Stealth BioTherapeutics as of its most recent SEC filing. 1.09% of the stock is owned by institutional investors.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Recommended Story: Why do companies engage in swaps?

Analyst Recommendations for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.